HN125: A novel immunoadhesin targeting MUC16 with potential for cancer therapy

Journal of Cancer

Volumn 2, Issue 1, 2011, Pages 280-291

  Xiang, Xinran ^a   Feng, Mingqian ^a   Felder, Mildred ^b   Connor, Joseph P ^b   Man, Yan Gao ^c   Patankar, Manish S ^b   Ho, Mitchell ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

Author keywords

Anti body dependent cellular cytotoxicity (ADCC); Human Fc fusion; Immunoadhesin; Mesothelin; Mesothelioma; Mucin MUC16 CA125; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; HN 125; HYBRID PROTEIN; IMMUNOGLOBULIN G1 ANTIBODY; MESOTHELIN; MUCIN; MUCIN 16; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER CELL; CANCER THERAPY; CELL ADHESION; CONTROLLED STUDY; CYTOTOXICITY; DRUG TARGETING; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCHEMISTRY; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PURIFICATION;

EID: 80053176340     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.2.280     Document Type: Article

References (48)

1. Frederick PJ, Straughn JM Jr, Alvarez RD, Buchsbaum DJ. Pre-clinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer. Gynecol Oncol 2009;113: 384-390.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60: 277-300.
3. Reichert JM. Antibody-based therapeutics to watch in 2011. MAbs 2011;3: 76-99.
4. Monk BJ, Choi DC, Pugmire G, Burger RA. Activity of bevaci-zumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer. Gynecol Oncol 2005;96: 902-905.
5. Monk BJ, Han E, Josephs-Cowan CA, Pugmire G, Burger RA. Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epi-thelial ovarian cancer. Gynecol Oncol 2006;102: 140-144.
6. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovari-an cancer or primary peritoneal cancer: a Gynecologic Oncol-ogy Group Study. J Clin Oncol 2007;25: 5165-5171.
7. Berchuck GC, Rodriguez A, Kamel RK, Dodge JT, Soper DL, et al. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of recep-tor expression with prognostic factors in patients with ovarian cancer. Am J Obstet Gynecol 1991;164: 669-674.
8. Scambia G, Benedetti Panici P, Battaglia F, Ferrandina G, et al. Significance of epidermal growth factor receptor in advanced ovarian cancer. J Clin Oncol 1992;10: 529-535.
9. Felip E, Del Campo JM, Rubio D, Vidal MT, Colomer R, et al. Overexpression of c-erbB-2 in epithelial ovarian cancer. Prog-nostic value and relationship with response to chemotherapy. Cancer 1995;75: 2147-2152.
10. Meden H, Marx D, Roegglen T, Schauer A, Kuhn W. Overex-pression of the oncogene c-erbB-2 (HER2/neu) and response to chemotherapy in patients with ovarian cancer. Int J Gynecol Pathol 1998;17: 61-65.
11. Aigner A, Hsieh SS, Malerczyk C, Czubayko F. Reversal of HER-2 over-expression renders human ovarian cancer cells highly resistant to taxol. Toxicology 2000;144: 221-228.
12. Høgdall EV, Christensen L, Kjaer SK, Blaakaer J, Bock JE, et al. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carci-noma: from the Danish MALOVA Ovarian Cancer Study. Cancer 2003;98: 66-73.
13. Camilleri-Broët S, Hardy-Bessard AC, Le Tourneau A, Paraiso D, Levrel O, et al. HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carci-noma: a multicenter study of the GINECO group. Ann Oncol 2004;15: 104-112.
14. Argüeso P, Spurr-Michaud S, Russo CL, Tisdale A, Gipson IK. MUC16 mucin is expressed by the human ocular surface epi-thelia and carries the H185 carbohydrate epitope. Invest Oph-thalmol Vis Sci 2003;44: 2487-2495.
15. Blalock TD, Spurr-Michaud SJ, Tisdale AS, Heimer SR, Gilmore MS, et al. Functions of MUC16 in corneal epithelial cells. Invest Ophthalmol Vis Sci 2007;48: 4509-4518.
16. Davies JR, Kirkham S, Svitacheva N, Thornton DJ, Carlstedt I. MUC16 is produced in tracheal surface epithelium and sub-mucosal glands and is present in secretions from normal hu-man airway and cultured bronchial epithelial cells. Int J Bio-chem Cell Biol 2007;39: 1943-1954.
17. Gipson IK. Distribution of mucins at the ocular surface. Exp Eye Res 2004;78: 379-388.
18. Gipson IK, Blalock T, Tisdale A, Spurr-Michaud S, Allcorn S, et al. MUC16 is lost from the uterodome (pinopode) surface of the receptive human endometrium: in vitro evidence that MUC16 is a barrier to trophoblast adherence. Biol Reprod 2008;78: 134-142.
19. Govindarajan B, Gipson IK. Membrane-tethered mucins have multiple functions on the ocular surface. Exp Eye Res 2010;90: 655-663.
20. Patankar MS, Yu J, Morrison JC, Belisle JA, Lattanzio FA, et al. Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125. Gynecol Oncol 2005;99: 704-713.
21. Belisle JA, Gubbels JA, Raphael CA, Migneault M, Rancourt C, et al. Peritoneal natural killer cells from epithelial ovarian can-cer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125). Immunology 2007;122: 418-429.
22. Belisle JA, Horibata S, Gubbels JA, Petrie S, Kapur A, et al. Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes. Mol Cancer 2010;9: 118.
23. Gubbels JA, Belisle J, Onda M, Rancourt C, Migneault M, et al. Mesothelin-MUC16 binding is a high affinity, N-glycan de-pendent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer 2006;5: 50.
24. Gubbels JA, Claussen N, Kapur AK, Connor JP, Patankar MS. The detection, treatment, and biology of epithelial ovarian cancer. J Ovarian Res 2010;3: 8.
25. Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur J Cancer 2008;44: 46-53.
26. Ho M, Bera TK, Willingham MC, Onda M, Hassan R, et al. Mesothelin expression in human lung cancer. Clin Cancer Res 2007;13: 1571-1575.
27. Yu L, Feng M, Kim H, Phung Y, Kleiner DE, et al. Mesothelin as a potential therapeutic target in human cholangiocarcinoma. J Cancer 2010;1: 141-149.
28. Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, et al. Binding of ovarian cancer antigen CA125/MUC16 to meso-thelin mediates cell adhesion. J Biol Chem 2004;279: 9190-9198.
29. Scholler N, Garvik B, Hayden-Ledbetter M, Kline T, Urban N. Development of a CA125-mesothelin cell adhesion assay as ascreening tool for biologics discovery. Cancer Lett 2007;247: 130-136.
30. Kaneko O, Gong L, Zhang J, Hansen JK, Hassan R, et al. A binding domain on mesothelin for CA125/MUC16. J Biol Chem 2009;284: 3739-49.
31. Mobus VJ, Baum RP, Bolle M, Kreienberg R, Noujaim AA, et al. Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer. Am J Obstet Gynecol 2003;189: 28-36.
32. Gordon AN, Schultes BC, Gallion H, Edwards R, Whiteside TL, et al. CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients. Gynecol Oncol 2004;94: 340-351.
33. Berek JS, Taylor PT, Gordon A, Cunningham MJ, Finkler N, et al. Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J Clin Oncol 2004;22: 3507-3516.
34. Chen Y, Clark S, Wong T, Chen Y, Chen Y, et al. Armed anti-bodies targeting the mucin repeats of the ovarian cancer anti-gen, MUC16, are highly efficacious in animal tumor models. Cancer Res 2007;67: 4924-4232.
35. Huang C. Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology. Curr Opin Biotechnol 2009;20: 692-699.
36. Ho M, Hassan R, Zhang J, Wang QC, Onda M, et al. Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. Clin Cancer Res 2005;11: 3814-3820.
37. Barouch DH, Yang ZY, Kong WP, Korioth-Schmitz B, Sumida SM, et al. A human T-cell leukemia virus type 1 regulatory el-ement enhances the immunogenicity of human immunodefi-ciency virus type 1 DNA vaccines in mice and nonhuman pri-mates. J Virol 2005;79: 8828-8834.
38. Ofek G, McKee K, Yang Y, Yang ZY, Skinner J, et al. Relation-ship between antibody 2F5 neutralization of HIV-1 and hy-drophobicity of its heavy chain third complementari-ty-determining region. J Virol 2010;84: 2955-2962.
39. Ho M, Feng M, Fisher RJ, Rader C, Pastan I. A novel high-affinity human monoclonal antibody to mesothelin. Int J Cancer 2011;128:2020-2030.
40. Roy A, Kucukural A, Zhang Y. I-TASSER: a unified platform for automated protein structure and function prediction. Nat Pro-toc 2010;5: 725-738.
41. Ho M, Segre M. Inhibition of cocaine binding to the human dopamine transporter by a single chain anti-idiotypic antibody: its cloning, expression, and functional properties. Biochim Bi-ophys Acta 2003;1638: 257-266.
42. Man YG, Tavassoli FA. A simple epitope retrieval method without the use of microwave oven or enzyme digestion. Appl Immunohistochem 1996;4: 139-141.
43. Hsiao YH, Siddiqui S, Man YG. Dual use of a single Wilms' tumor 1 immunohistochemistry in evaluation of ovarian tu-mors: a preliminary study of 20 cases. J Cancer 2010;1: 93-97.
44. Coligan JE, Kruisbeek AM, Marguiles DH, Shevach EM, Strober WE. Measurement of cytotoxic activity of NK/LAK cells. Curr Protoc Immunol 1996;3: Unit7-18.
45. Bast RC Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB, et al. Reactivity of a monoclonal antibody with human ovarian car-cinoma. J Clin Invest 1981;68: 1331-1337.
46. Berek JS, Taylor PT, Nicodemus CF. CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in ad-vanced ovarian cancer. J Immunother 2008;31: 207-214.
47. Xiang X, Phung Y, Feng M, Nagashima K, Zhang J, Broaddus VC, Hassan R, Fitzgerald D, Ho M. The development and characterization of a human mesothelioma in vitro 3D model toinvestigate immunotoxin therapy. PLoS One. 2011 Jan 31;6(1):e14640.
48. Feng M, Zhang J, Anver M, Hassan R, Ho M. In vivo imaging of human malignant mesothelioma grown orthotopically in the peritoneal cavity of nude mice. J Cancer. 2011 Mar 1;2:123-31.